score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Investigate Actionability - High	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.D594Y	0.0565	230.0	0.0	0.0		Investigate Actionability - High	Dabrafenib + Trametinib	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Tafinlar [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2018.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/202806s008lbl.pdf	Investigate Actionability - High	Panitumumab	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability - High	0.0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	0				BRAF p.D594Y (Missense)	1.0	MEL-IPI_Pat92	MEL-IPI_Pat92-Tumor-SM-4DK3I	MEL-IPI_Pat92-Normal-SM-4NFWO
Investigate Actionability - High	Clinical evidence		Clinical evidence	Somatic Variant	NRAS	Missense	p.Q61K	0.1298	262.0	0.0	0.0		Investigate Actionability - High	Selumetinib	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956							Investigate Actionability - High	0.0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0				NRAS p.Q61K (Missense)	1.0	MEL-IPI_Pat92	MEL-IPI_Pat92-Tumor-SM-4DK3I	MEL-IPI_Pat92-Normal-SM-4NFWO
Investigate Actionability - Low	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Nonsense	p.E611*	0.0379	211.0	0.0	0.0		Investigate Actionability - Low	Dabrafenib + Trametinib	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Tafinlar [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2018.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/202806s008lbl.pdf	Investigate Actionability - Low	Panitumumab	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability - Low	0.0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	0				BRAF p.E611* (Nonsense)	1.0	MEL-IPI_Pat92	MEL-IPI_Pat92-Tumor-SM-4DK3I	MEL-IPI_Pat92-Normal-SM-4NFWO
Investigate Actionability - Low	Preclinical			Somatic Variant	FBXW7	Nonsense	p.R658*	0.0521	96.0	0.0	0.0		Investigate Actionability - Low	Sirolimus	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981												0				FBXW7 p.R658* (Nonsense)		MEL-IPI_Pat92	MEL-IPI_Pat92-Tumor-SM-4DK3I	MEL-IPI_Pat92-Normal-SM-4NFWO
Biologically Relevant				Somatic Variant	FGFR2	Nonsense	p.R210*	0.044000000000000004	91.0	0.0	0.0																			0				FGFR2 p.R210* (Nonsense)		MEL-IPI_Pat92	MEL-IPI_Pat92-Tumor-SM-4DK3I	MEL-IPI_Pat92-Normal-SM-4NFWO
Biologically Relevant				Microsatellite Stability	Supporting variants		DOCK3 Amplification, PRDM2 p.703_704insP (Insertion), MSH3 p.AAAAAA52del (Deletion)																							0				Supporting variants: DOCK3 Amplification, PRDM2 p.703_704insP (Insertion), MSH3 p.AAAAAA52del (Deletion)		MEL-IPI_Pat92		
Biologically Relevant				Mutational Signature	COSMIC Signature 1		0.325																							0				COSMIC Signature 1 (32%)		MEL-IPI_Pat92		
Biologically Relevant				Mutational Signature	COSMIC Signature 18		0.54																							0				COSMIC Signature 18 (54%)		MEL-IPI_Pat92		
